Urologic Cancer Research

Urologic cancer researchers study tumors that affect the urinary tract, including cancers of the kidney, bladder and prostate. The frequency of these types of cancer varies, depending on a person’s ethnic and racial background. At the Henry Ford Cancer, we’re working to understand these variations. Our goal is to use our skills in surgical treatment and genetic research to develop new ways to diagnose and treat urologic cancer.

We’ve built our research programs on close interaction between basic scientists (Ph.D.-educated scientists who work in the lab) and practicing clinicians (doctors who work directly with patients). Henry Ford patients receive expert care from the Vattikuti Urology Institute, our dedicated center for expertise in bladder, kidney, prostate and urinary conditions.

Our urologic cancer research

We are investigating urologic cancer treatments from genetic analysis through surgery, radiation, chemotherapy and pharmaceuticals (drugs).

Our urologic cancer research includes:

  • Prostate cancer diagnosis and planning:
    • Discovering molecular markers for early detection and prognosis of prostate cancer, and novel targets for prostate cancer treatment
    • Identifying RNA-based markers that can detect prostate cancer earlier and more accurately than currently possible
    • Determining whether markers of early prostate disease differ between African-American and European-American men
    • Identifying small molecules that can selectively disrupt calmodulin (calcium-modulated protein) interaction to break down the androgen receptor (androgens male hormones that help the prostate and most prostate tumors to grow)
    • Predicting prostate cancer outcomes in African-American men
    • Identifying markers of metastatic prostate cancer to distinguish patients with organ-confined disease versus metastatic disease at the time of radical prostatectomy (RP), based on long-term follow-up after RP
  • Prostate cancer treatment:
    • Using 5-lipoxygenase and the proteins involved in its metabolite-induced signaling pathway as novel therapeutic targets for the treatment of prostate cancer
    • Developing approaches to identify androgen receptor-interacting telomeric proteins that can be targeted for the treatment of prostate cancer
    • Understanding the molecular mechanisms of chemotherapy resistance and applying this knowledge to the care of patients with metastatic prostate cancer
    • Using oleanolic acid and ursolic acid (naturally occurring triterpenoids that have been used in traditional medicine as antibacterial, anti-inflammatory and anticancer agents) to treat prostate cancer
  • Other urologic cancer research:
    • Improving robotic surgical techniques for bladder and kidney cancer
    • Identifying and using biomarkers and genes for the diagnosis, prognosis and treatment of bladder, kidney and prostate cancer
    • Developing and applying statistical methods for observational and correlated data, and quantitative synthesis of medical evidence

Spotlight: Prostate cancer genomic research

Our researchers are working to understand the genetic indications of prostate cancer -- the signs that a person’s cells may be more prone to developing a prostate tumor.

To investigate this question, our researchers are turning to the genome (a person’s complete set of DNA, including all genes). Genes are tiny strands of material in every cell that instruct cells how to behave. Scientists believe genes hold the “instructions” for certain kinds of cancer. As a result, people who carry specific genes may have a higher likelihood of experiencing that type of tumor, such as prostate cancer.

One important piece of the puzzle is knowing that different genetic groups of people have different gene markers that indicate a higher risk for prostate or other cancers. Now, we’re working to discover and understand those gene markers. Ultimately, we want to deliver individualized treatment, so that patients can have faster and more complete recoveries.

Ongoing genomic research for prostate cancer

Thanks to earlier research, we can take a sample of a tumor and analyze it to understand a person’s genetic background. Our ongoing work involves refining these techniques to help doctors identify prostate cancer -- and its associated risks -- more quickly and more accurately.

Our current research includes:

  • Personalized medicine: By identifying how tumors’ genetic markers align with certain types of tumors, we can prescribe more appropriate treatment, rather than trying the same standard treatment first on everyone. Treatments based on genetic markers received approval from the U.S. Food and Drug Administration (FDA) for breast and lung cancer, for example. Learn more about our precision medicine cancer research.
  • Molecular markers: We’re working to identify new molecular markers so that we can divide types of prostate cancer into distinct groups. Then scientists can develop appropriate therapeutics (cancer-fighting drugs) to target those specific markers. Read more about our developmental therapeutics.
  • Prostate cancer markers in urine: Doctors can detect some genetic markers for prostate cancer without performing a biopsy, using an FDA-approved urine test. Now, researchers are working to refine urine tests so that the lab can determine the type of prostate cancer from those same genetic markers in urine. When we succeed, patients could have a noninvasive diagnosis and be able to begin the correct treatment immediately.
  • Tumor heterogeneity (differences among tumors): Many patients who have prostate cancer will have multiple tumors in a very small area. We are working to understand whether these individual tumors are identical at the molecular level. This research takes the identification and treatment of prostate cancer beyond the level of visual appearance. Eventually, understanding tumor heterogeneity will allow us to treat all tumors the first time, so that the cancer will be less likely to spread or metastasize after initial treatment. Through a U.S. Department of Defense (DoD) grant, we also are studying the differences in the incidence and prevalence of these markers between European-American and African-American men. Read more about our grant-funded cancer research.
  • Prostate cancer in African-American men: To date, no one has studied in detail the incidence of prostate cancer markers in African-American populations. Since 2014, our researchers have discovered striking differences among European-American and African-American men who have genetic markers for prostate cancer. For example, one marker is present in 50 percent of European-American men, but tests find it in fewer than 20 percent of African-American men. Another marker that appears in only 10 percent of European-American men exists in up to 40 percent of African-American men. In particular, genetic markers associated with more aggressive prostate cancer are higher among African-American populations. If a doctor knows that a man is likely to have an aggressive type of cancer, the doctor may be able to recommend a more aggressive treatment right away -- potentially saving lives.

Urologic cancer research resources at Henry Ford

The urologic cancer program at the Henry Ford Cancer Institute includes investigators from the Vattikuti Urology Institute  and the Department of Surgery.

Our program also benefits from resources at Henry Ford including:

  • Prostate tissue biorepository: Our prostate tissue bank includes more than 10,000 vials of cancerous and adjacent normal prostate tissue specimens.
  • Robosurge database: Robosurge is a dedicated database of more than 5,000 robotic-assisted prostatectomy cases performed at our institution since 2001. This database contains patients' demographics, pre-operative health status, disease characteristics per biopsy and surgical specimen, and surgical parameters.

Get involved with urologic cancer research

You can participate in our urologic cancer research work, whether you are a researcher or a patient.

  • Find a clinical trial: We frequently conduct clinical trials and study tissue samples from prostate biopsies. A clinical trial may give you new treatment opportunities that aren’t yet widely available. Learn more about clinical trials.
  • Become a Henry Ford researcher: We may be accepting researchers to join our urologic cancer genetic research work. Join our research team.
  • Support urologic cancer research: Henry Ford’s Cancer Research Advisory Group (CRAG) provides funding and resources to help advance our research. Learn how you can support cancer research.

Our researchers

Our urologic cancer researchers include both research specialists and doctors who work directly with patients. Below, you can learn more about our current researchers and how to join our research team.

Urologic cancer research leaders

Urologic cancer research scientific members

Urologic cancer clinical members

Publications in urologic cancer research

We share our work regularly with the medical research community through publication in scientific journals. Search the publications below for topics that interest you.

Publications by Henry Ford urologic cancer researchers

Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, Briganti A and Menon M. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. World journal of urology. 2016.

Abdollah F, Klett DE, Sammon JD, Dalela D, Sood A, Hsu L, Diaz M, Gupta N, Peabody JO, Trinh QD and Menon M. Predicting lymph node invasion in patients treated with robot-assisted radical prostatectomy. Canadian journal of urology. 2016; 23(1):8141–8150.

Abdollah F, Moschini M, Sood A, Sammon J, Dalela D, Hsu L, Beyer B, Haese A, Graefen M, Gandaglia G, Montorsi F, Briganti A and Menon M. When should a positive surgical margin ring a bell? An analysis of a multi-institutional robot-assisted laparoscopic radical prostatectomy database. Journal of endourology. 2016; 30(2):201–207.

Abdollah F, Sun M, Sammon JD, Choueiri TK, Menon M, Weissman JS and Trinh QD. Prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States: A nationwide survey analysis. JAMA oncology. 2016.

Abdollah FFH, Dalela D, Sammon J, Sood A, Fossati N, Gandaglia G, Suardi N, Gaboardi F, Pini G, Jeong W, Rogers C, Peabody J, Montorsi F, Briganti A, Menon M and Dalela D. Late recovery of erectile function in men treated with robotic-assisted laparoscopic radical prostatectomy (RALP): A novel nomogram development and validation. European Urology, Supplements. 2016; 15(3):E447.

Abdollah FFH, Dalela D, Sood A, Meyer C, Sun M, Trinh QD, Menon M, Sammon J and Dalela D. The impact of 2012 United States Preventive Services Task Force (USPSTF) panel update on PSA screening practice: A nationwide, and state-by-state level analyses. European Urology, Supplements. 2016; 15(3):E91+E91a.

Abdollah FFH, Dalela D, Sood A, Sammon J, Karabon P, Meyer C, Sun M, Choueiri T, Menon M, Trinh QD and Dalela D. Temporal trends in prostate cancer (PCa) risk group stratification following the 2008 United States preventive services task force recommendations. European Urology, Supplements. 2016; 15(3):E726.

Alikhan M, Song JY, Sohani AR, Moroch J, Plonquet A, Duffield AS, Borowitz MJ, Jiang L, Bueso-Ramos C, Inamdar K, Menon MP, Gurbuxani S, Chan E, Smith SM, Nicolae A, Jaffe ES, et al. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3-/dimCD4+ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2016.

Aljundi L, Miller N, Taylor A, Hung J and Hwang C. Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer. J Clin Oncol. 2016; 34.

Cole AP, Leow JJ, Chang SL, Chung BI, Meyer CP, Kibel AS, Menon M, Nguyen PL, Choueiri TK, Reznor G, Lipsitz SR, Sammon JD, Sun M and Trinh QD. Surgeon and hospital-level variation in the costs of robot-assisted radical prostatectomy. Journal of urology. 2016.

Cole AP, Trinh QD, Sood A and Menon M. The rise of robotic surgery in the new millennium. Journal of urology. 2016.

Dalela D and Menon M. Contemporary trends in radical prostatectomy in the United States: Open vs minimally invasive surgery. Mayo Clinic proceedings. 2016; 91(1):1-2.

Dalela D, Jindal T, Menon M and Abdollah F. Improved survival with local treatment of prostate cancer in men with metastatic disease: Look before you leap. J Clin Oncol. 2016:Jco2016696617.

Dalela D, Karabon P, Sammon J, Sood A, Loppenberg B, Trinh QD, Menon M and Abdollah F. Generalizability of the prostate cancer intervention versus observation trial (PIVOT) results to contemporary North American men with prostate cancer. European urology. 2016.

Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunju LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KM, Keller ET, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2016.

Diaz M, Chang S and Singer M. Adherence to dietary indexes by diabetes and hypertension status among PLCO cancer screening trial participants. Adv Nutr. 2016; 7(1):38A.

East E, Fullen DR, Arps D, Patel RM, Palanisamy N, Carskadon S and Harms PW. Morpheaform basal cell carcinomas with areas of predominantly single-cell pattern of infiltration: Diagnostic utility of p63 and cytokeratin. American journal of dermatopathology. 2016.

Eleswarapu S, Sood A, Abdollah F, Sammon J, Jeong W, Dalela D, Klett D, Peabody J, Eswara J, Menon M, Trinh QD and Dabaja A. Complications following male reconstructive urologic surgery. Eur Urol, Supplements. 2016; 15(3):E326.

Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JM and Tomlins SA. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2016; 29(2):157–165.

Gadde R, Gulati R, Inamdar KV, Michalowski S and Menon M. Cytogenetic analysis is crucial in the early diagnosis of indolent t-cell prolymphocytic leukemia. Lab Invest. 2016; 96:345A–345A.

Ghani KR, Miller DC, Linsell S, Brachulis A, Lane B, Sarle R, Dalela D, Menon M, Comstock B, Lendvay TS, Montie J and Peabody JO. Measuring to improve: Peer and crowd-sourced assessments of technical skill with robot-assisted radical prostatectomy. European urology. 2016.

Gulati R, Alkhatib Y, Donthireddy V, Felicella MM, Menon MP and Inamdar KV. Isolated ocular manifestation of relapsed chronic myelogenous leukemia presenting as myeloid blast crisis in a patient on imatinib therapy: A case report and review of the literature. Case reports in pathology. 2015; 2015:380451.

Hanna N, Zavaski M, Gelpi-Hammerchmidt F, Meyer C, Sammon J, Kibel A, Menon M, Leow J, Sun M, Abdollah F and Trinh QD. Informed decision-making for prostate-specific antigen screening. Eur Urol, Supplements. 2016; 15(3):E94.

Hanske J, Meyer CP, Sammon JD, Choueiri TK, Menon M, Lipsitz SR, Noldus J, Nguyen PL, Sun M and Trinh QD. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive medicine. 2016.

Harms PW, Hocker TL, Zhao L, Chan MP, Andea AA, Wang M, Harms KL, Wang ML, Carskadon S, Palanisamy N and Fullen DR. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Human pathology. 2016.

Huang KC, Begin LR, Palanisamy N, Donnelly B and Bismar TA. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. Urologic oncology. 2015.

Hung J, Taylor AR, Divine GW, Hafron JM and Hwang C. The effect of time to castration resistance on outcomes with abiraterone and enzalutamide in metastatic prostate cancer. Clinical genitourinary cancer. 2016.

Hussein AA, Saar M, May PR, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Shamim Khan M, Menon M, Peabody JO, Hosseini A, Gaboardi F, Mottrie A, et al. Early oncologic failure after robot-assisted radical cystectomy: Results from the international robotic cystectomy consortium. Journal of urology. 2016.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH and Heath EI. Anti-androgenic activity of absorption-enhanced 3, 3’-diindolylmethane in prostatectomy patients. Am J Transl Res. 2016; 8(1):166–176.

Jamal M, Williamson SR, Diaz-Insua M, Menon M, Stricker H, Peabody J, Rogers CG and Gupta NS. Clinical significance of percentage of gleason pattern 4 in gleason score 7 prostate cancer at radical prostatectomy. Lab Invest. 2016; 96:240A.

Jamal M, Williamson SR, Diaz-Insua M, Menon M, Stricker H, Peabody J, Rogers CG and Gupta NS. Significance of percentage of gleason pattern 4 at needle biopsy in predicting final gleason score and correlation with pathologic outcomes at radical prostatectomy. Lab invest. 2016; 96:240A.

Jeong W, Kumar R and Menon M. Past, present and future of urological robotic surgery. Investigative and clinical urology. 2016; 57(2):75–83.

Jiang F, Cabrera Fernandez DF, Church J, Gulati R, Taylor A, Menon M and Kuriakose P. Correlation between peripheral blood counts and day 14 bone marrow biopsy in acute myeloid leukemia during induction chemotherapy. Blood. 2015; 126(23):3.

Jindal T, Seisen T, Sood A, Menon M and Abdollah F. The importance of adjuvant therapy in patients with node-positive prostate cancer: A nationwide validation study. Urologic oncology. 2016.

Leow JJ, Chang SL, Meyer CP, Wang Y, Hanske J, Sammon JD, Cole AP, Preston MA, Dasgupta P, Menon M, Chung BI and Trinh QD. Robot-assisted versus open radical prostatectomy: A contemporary analysis of an all-payer discharge database. European urology. 2016.

Leyh-Bannurah SR, Gazdovich S, Budaus L, Zaffuto E, Dell'Oglio P, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Graefen M and Karakiewicz PI. Population-based external validation of the updated 2012 partin tables in contemporary north american prostate cancer patients. Prostate. 2016.

Loppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, Sun M, Noldus J, Peabody JO, Trinh QD, Menon M and Abdollah F. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. European urology. 2016.

Löppenberg B, Meyer C, Hanna N, Cole A, Vetterlein M, Menon M, Sammon J, Leow J, Kibel A and Trinh QD. Sling procedures for female stress incontinence: Does surgical specialty matter? Eur Urol, Supplements. 2016; 15(3):E7.

Lu ZC, Williamson SR, Diaz-Insua M, Stricker H, Menon M and Gupta NS. Pathologic outcomes and biochemical recurrence (BCR) free survival in men younger than 45 years with prostate cancer (PCa) treated with robotic radical prostatectomy (RRP). Lab Invest. 2016; 96:247A.

Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey D, Diehl JA and Palanisamy V. RNA-binding protein FXR1 regulates p21 and TERC RNA to bypass p53-mediated cellular senescence in OSCC. PLoS genetics. 2016; 12(9):e1006306.

Mani RS, Amin MA, Li X, Kalyana-Sundaram S, Veeneman BA, Wang L, Ghosh A, Aslam A, Ramanand SG, Rabquer BJ, Kimura W, Tran M, Cao X, Roychowdhury S, Dhanasekaran SM, Palanisamy N, et al. Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer. Cell reports. 2016; 17(10):2620–2631.

Meyer C, Friedlander D, Choi K, Cole A, Abdollah F, Hanske J, Zavaski M, Sammon J, Leow J, Menon M, Sun M, Kibel A and Trinh QD. A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer. Eur Urol, Supplements. 2016; 15(3):E93.

Meyer C, Sood A, Abdollah F, Sammon J, Vetterlein M, Löppenberg B, Hanske J, Leow J, Cole A, Sun M, Menon M and Trinh QD. Minimally invasive vs open radical prostatectomy: An analysis of 30-day postoperative complications, unplanned readmissions, and mortality. Eur Urol, Supplements. 2016; 15(3):E443.

Meyer C, Trinh QD, Vetterlein M, Löppenberg B, Hanske J, Leow J, Sammon J, Abdollah F, Menon M, Kibel A, Chang S, Choueiri T and Sun M. Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival. Eur Urol, Supplements. 2016; 15(3):E755.

Meyer C, Zavaski M, Hanske J, Friedlander D, Cheng P, Menon M, Kibel A, Cole A, Leow J, Abdollah F, Sun M, Sammon J and Trinh QD. Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations. Eur urol, supplements. 2016; 15(3):E90.

Modi D, Hwang C, Mamdani H, Kim S, Gayar H, Vaishampayan U, Joyrich R and Heath EI. Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer. Clinical genitourinary cancer. 2016.

Patel AA, Mahajan A, Benjo A, Pathak A, Kar J, Jani VB, Annapureddy N, Agarwal SK, Sabharwal MS, Simoes PK, Konstantinidis I, Yacoub R, Javed F, El Hayek G, Menon MC and Nadkarni GN. A nationwide analysis of outcomes of weekend admissions for intracerebral hemorrhage shows disparities based on hospital teaching status. Neurohospitalist. 2016; 6(2):51–58.
Sarveswaran S, Varma N, Morisetty S and Ghosh J. Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase. Oncotarget. 2016.

Saste AB, Gulati R, Kuriakose P, Inamdar K, Karner K, Carey J and Menon M. Prognostic impact of aberrant t/NK cell marker expression in AML. J Clin Oncol. 2016; 34.

Schmid M, Krishna N, Ravi P, Meyer CP, Becker A, Dalela D, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Trinh QD and Sun M. Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic oncology. 2016.

Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Roupret M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M and Abdollah F. Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma. European urology. 2016.

Smith SC, Palanisamy N, Martin E, Almenara J, McHugh JB, Choi EK, Lucas DR, Betz BL, Thomas D and Patel RM. The utility of ETV1, ETV4, and ETV5 RNA in situ hybridization in the diagnosis of CIC-DUX4 sarcomas. Histopathology. 2016.

Sood A, Abdollah F and Menon M. Je le pansai, Dieu le guerit. European urology. 2016.

Sood A, Abdollah F, Sammon JD, Arora N, Weeks M, Peabody JO, Menon M and Trinh QD. Postoperative sepsis prediction in patients undergoing major cancer surgery. Journal of surgical research. 2016; 209:60–69.

Sood A, Abdullah NM, Abdollah F, Abouljoud MS, Trinh QD, Menon M and Sammon JD. Rates of kidney transplantation from living and deceased donors for blacks and whites in the united states, 1998 to 2011. JAMA internal medicine. 2015; 175(10):1716–1718.

Sood A, Ghosh P, Jeong W, Bhandari M, Ahlawat R and Menon M. Robotic kidney transplantation with regional hypothermia: Results from a prospective two-arm non-randomized controlled trial (Ideal phase 2b). Eur urol, supplements. 2016; 15(3):E715.

Sood A, Hemal AK, Assimos DG, Peabody JO, Menon M and Ghani KR. Robotic anatrophic nephrolithotomy utilizing near infrared fluorescence image-guidance: Idea, development, exploration, assessment, long-term monitoring (ideal) stage 0 animal model study. Urology. 2016.

Sood A, Klett DE, Abdollah F, Sammon JD, Pucheril D, Menon M, Jeong W and Peabody JO. Robot-assisted partial cystectomy with intraoperative frozen section examination: Evolution and evaluation of a novel technique. Investigative and clinical urology. 2016; 57(3):221–228.

Sood A, Majumder K, Kachroo N, Sammon JD, Abdollah F, Schmid M, Hsu L, Jeong W, Meyer CP, Hanske J, Kalu R, Menon M and Trinh QD. Adverse event rates, timing of complications, and the impact of specialty on outcomes following adrenal surgery: An analysis of 30-day outcome data from the american college of surgeons national surgical quality improvement program (acs-nsqip). Urology. 2015.

Sood A, Sammon J, Abdollah F, Klett D, Dalela D, Kibel A, Pucheril D, Schmid M, Jeong W, Dabaja A, Rogers C, Peabody J, Menon M, Trinh Q and Abdollah F. Complications after adrenalectomy-does the speciality matter? Eur urol, supplements. 2016; 15(3):E485.

Thamilselvan V, Menon M and Thamilselvan S. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants and Akt in preclinical models: New hope for patients with prostate cancer. International journal of cancer Journal international du cancer. 2016.

Trinh QD, Li H, Meyer CP, Hanske J, Choueiri TK, Reznor G, Lipsitz SR, Kibel AS, Han PK, Nguyen PL, Menon M and Sammon JD. Determinants of cancer screening in Asian-Americans. Cancer causes & control: CCC. 2016.

Vetterlein M, Meyer C, Löppenberg B, Sammon J, Hanske J, Menon M, Preston M, Chun F, Kibel A, Fisch M and Trinh QD. Radical cystectomy for bladder cancer vs non-malignant indications: Preoperative predictors of perioperative outcomes in a sample of 3269 patients. Eur urol, supplements. 2016; 15(3):E632.

Walz J, Epstein JI, Ganzer R, Graefen M, Guazzoni G, Kaouk J, Menon M, Mottrie A, Myers RP, Patel V, Tewari A, Villers A and Artibani W. A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: An update. European urology. 2016.

Wang L, Diaz M, Stricker H, Peabody JO, Menon M and Rogers CG. Adding a newly trained surgeon into a high-volume robotic prostatectomy group: are outcomes compromised? Journal of robotic surgery. 2016.

Wang L, Diaz M, Stricker H, Peabody JO, Menon M and Rogers CG. Erratum to: Adding a newly trained surgeon into a high-volume robotic prostatectomy group: are outcomes compromised? Journal of robotic surgery. 2016.

Williamson SR, Chitale DA, Favazza L, Barod R, Rogers CG, Palanisamy N and Gupta NS. Clear cell renal cell tumors with intact VHL and chromosome 3p: how many entities exist? Lab Invest. 2016; 96:271A.

Williamson SR, Eble JN and Palanisamy N. Sclerosing TFEB rearrangement renal cell carcinoma: A recurring histologic pattern. Human pathology. 2016.

Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, Gupta NS, Chitale DA, Kalyana-Sundaram S and Palanisamy N. Renal cell carcinoma with chromosome 6p amplification including the tfeb gene: A novel mechanism of tumor pathogenesis? American journal of surgical pathology. 2016.

Williamson SR, Grignon DJ, Favazza L, Gupta NS, Chitale DA and Palanisamy N. Chromosome 6p amplification including the TFEB gene: a novel mechanism of renal cell carcinoma pathogenesis? Lab invest. 2016; 96:270A–271A.

Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, Burness ML, Azizi E, Simeone DM, Wicha MS, Kim J and Nagrath S. Tunable thermal-sensitive polymer-graphene oxide composite for efficient capture and release of viable circulating tumor cells. Advanced materials (Deerfield Beach, Fla). 2016.

Zaffuto E, Gazdovich S, Leyh-Bannurah SR, Huland H, Abdollah F, Shariat SF, Menon M, Briganti A, Montorsi F and Karakiewicz PI. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. International journal of urology: official journal of the Japanese Urological Association. 2016.

Zhang Z, Shiratsuchi H, Palanisamy N, Nagrath S and Ramnath N. Expanded ctcs from a patient with alk positive lung cancer present eml4-alk rearrangement along with resistance mutation and enable drug sensitivity testing: A case study. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2016.


Cookie Consent

We use cookies to improve your website experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement  to learn what information we collect and how we use it.

Accept all